General Information
Revision date
2018-10-02
Product name
Neurotoxin from Organism (Clostridium botulinum) Lyophilized Drug Product
Product Synonyms
Botox
1.2.1 Relevant identified uses
Acetylcholine release inhibitor and Neuromuscular blocking agent for OAB, Prophylaxis of headaches in adults with chronic migraine, spasticity in adults, cervical dystonia in adults,
Manufacturer Name
Allergan plc
Emergency telephone
Call CHEMTREC Day or Night
Icons in SDS
Company Information
company name
Allergan plc
e-mail address of the competent person responsible for the Safety Data Sheet
SDS@Allergan.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H361
Hazard statements
Code
Statements
H361
Suspected of damaging fertility or the unborn child
Section 2
2.1 Classification of the substance or mixture
OSHA Regulatory Status This chemical is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200) Reproductive toxicity Category 2
2.2 Label elements
Emergency Overview Warning
Hazard statements
H361 - Suspected of damaging fertility or the unborn child The product contains no substances which at their given concentration, are considered to be hazardous to health Appearance Dehydrated product Physical state Solid Odor No information available Contained in a Vial Chemical Name Symptoms Botulinum toxin type A The most common adverse reactions (≥5% and >placebo) are OAB urinary tract infection, dysuria, urinary retention; Detrusor Overactivity associated with a neurologic condition urinary tract infection, urinary retention; Chronic Migraine neck pain, headache; Spasticity pain in extremity; Cervical Dystonia dysphagia, upper respiratory infection, neck pain, headache, increased cough, flu syndrome, back pain, rhinitis; Axillary Hyperhidrosis: injection site pain and hemorrhage, non-axillary sweating, pharyngitis, flu syndrome Chemical Name
Medical Conditions Generally Aggravated by Exposure
Botulinum toxin type A Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation, Infection at the proposed injection site, Intradetrusor Injections: Urinary Tract Infection or Urinary Retention
Further information
Unknown Acute Toxicity 35.7% of the mixture consists of ingredient(s) of unknown toxicity Over the counter drugs in their solid form are considered exempt under the criteria of the Federal OSHA Hazard Communication Standard 20 CFR 1910.1200. However, in an industrial setting where a component's occupational exposure limit may be surpassed, than can be considered hazardous